Axonics announces definitive agreement to be acquired by boston scientific

Irvine, calif.--(business wire)--axonics, inc. (nasdaq: axnx) today announced that it has entered into a definitive agreement to be acquired by boston scientific corporation (nyse: bsx) for $71 in cash per share, representing an equity value of approximately $3.7 billion. axonics brings a complementary product portfolio to the boston scientific urology business. axonics has pioneered and introduced significant enhancements to sacral neuromodulation therapy for bladder and bowel dysfunction and.
BSX Ratings Summary
BSX Quant Ranking